Site Search

CF Foundation's $1 Million Investment Helped Drug Known as Cayston® Become a Reality

Proposed legislation has the potential to revitalize the global marketplace for novel antibiotics, bringing urgently needed medicines for drug-resistant infections to patients.

Today, the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis. About 17% of individuals with CF who had Pseudomonas infections last year had multi-drug resistant strains.

A new inhaled antibiotic for the treatment of cystic fibrosis called Cayston^® is now available for patients through select specialty pharmacies, including the CF Services Pharmacy. 

A key focus of this year's North American Cystic Fibrosis Conference (NACFC) was the progress of the more than 30 potential new therapies moving through the CF Foundation's drug development pipeline.